Defining 'Substantial Efficacy': Post Hoc Analysis OK (When US FDA Does It)
This article was originally published in SRA
The US Food and Drug Administration's approach to weighing "non-positive" efficacy data against the results from two successful clinical trials for an antidepressant drew protests from some members of its Psychopharmacologic Drugs Advisory Committee on Dec. 1. The development could have implications beyond antidepressant drug development and highlights the potential need for FDA guidance on this issue.
You may also be interested in...
Biogen and Eisai's surprise decision to advance Alzheimer’s antibody despite mixed clinical results could follow a similar path as pioneering neurodegenerative therapies Xenazine and Rilutek, or more recent Parkinson’s drug Nourianz – or could end with suspended development, like Kyndrisa.
Use of expedited pathway for Biogen's Alzheimer's drug was discussed at a center director briefing in late April, where it garnered backing from several senior CDER officials, as well as CBER director Peter Marks and OCE director Richard Pazdur.
Pink Sheet reporter and editors discuss whether emotion could be removed from US FDA advisory committees, adverse events and advancing science in gene therapy development, and Capitol Hill’s interest in the ongoing user fee negotiations.